Impact Factor 4.137 | CiteScore 4.28
More on impact ›
The field of radiation oncology is currently entering a new frontier of more personalized cancer treatment.
We are being led into this new frontier by the explosion of information in cancer biology. From the maturation of 3-dimensional (3-D) to 4- dimensional (4-D) photon and proton radiation planning and delivery, and the refinement of more sensitive tumor-imaging technologies for radiation therapy targeting, to an improved understanding of how best to integrate radiation therapy with conventional chemotherapy, newer biologics, as well as surgery, in a multi-modality approach.
This Section welcomes basic and clinical research relating to all aspects of radiation oncology. We are specifically interested in papers on the following topics:
Indexed in: PubMed, PubMed Central, Scopus, Google Scholar, DOAJ, CrossRef, Chemical Abstracts Service (CAS), Science Citation Index Expanded, CLOCKSS
PMCID: all published articles receive a PMCID
Radiation Oncology welcomes submissions of the following article types: Case Report, Clinical Trial, Correction, Editorial, General Commentary, Hypothesis and Theory, Methods, Mini Review, Opinion, Original Research, Perspective, Review, Specialty Grand Challenge, Systematic Review and Technology and Code.
All manuscripts must be submitted directly to the section Radiation Oncology, where they are peer-reviewed by the Associate and Review Editors of the specialty section.
Articles published in the section Radiation Oncology will benefit from the Frontiers impact and tiering system after online publication. Authors of published original research with the highest impact, as judged democratically by the readers, will be invited by the Chief Editor to write a Frontiers Focused Review - a tier-climbing article. This is referred to as "democratic tiering". The author selection is based on article impact analytics of original research published in all Frontiers specialty journals and sections. Focused Reviews are centered on the original discovery, place it into a broader context, and aim to address the wider community across all of Oncology.
Avenue du Tribunal Fédéral 34
CH – 1005 Lausanne
Tel +41(0)21 510 17 40
Fax +41 (0)21 510 17 01
For all queries regarding manuscripts in Review and potential conflicts of interest, please contact firstname.lastname@example.org
For queries regarding Research Topics, Editorial Board applications, and journal development, please contact email@example.com